Clinical Neuropsychology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • J Neuropsychopharmacol Mental Health,
  • DOI: 10.4172/2472-095X.1000e106

Second Generation Long-acting Injectable Antipsychotics as a First-lineTreatment of First Episode Schizophrenia:Lights and Shadows

Domenico De Berardis1,2,3*
1Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, , ASL 4 Teramo, Italy
2Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University “G. D’Annunzio”, , Chieti, Italy
3Polyedra Clinical Group, , Teramo, Italy
*Corresponding Author : Domenico De Berardis MD, PhD, National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, “G. Mazzini” Hospital, Pizza Italia 1, Teramo 64100, Italy, Tel: +39 0861429708, Email: domenico.deberardis@aslteramo.it

Received Date: Apr 25, 2016 / Accepted Date: Apr 27, 2016 / Published Date: Apr 29, 2016

Citation: De Berardis D (2016) Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia: “Lights” and “Shadows”. J Neuropsychopharmacol Mental Health 1: e106. Doi: 10.4172/2472-095X.1000e106

Copyright: © 2016 De Berardis D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top